NEW YORK – Verizon, Bloomberg Media, Zixi and Amazon Web Services (AWS) are working together to test how 5G and mobile edge computing can transform how global business news is produced, delivered and consumed. Using Verizon 5G Edge with AWS Wavelength, Bloomberg Media will be able to package and deliver live 4K Ultra High Definition (UHD) content without the need for satellites, allowing for fast and efficient content delivery.
FRAMINGHAM, Mass., Feb. 14, 2022 /PRNewswire/ — Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, today announced they have secured $41.5M in funding. The series C-2 funding round, led by New Era Capital Partners and includes Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech, will be used to fuel company growth and launch newly developed solutions across all markets, with a focus on precision oncology.
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for SQZ-eAPC-HPV, authorizing the company to proceed with initiating a Phase 1/2 clinical trial of the novel cell therapy candidate. The company plans to initiate its COMMANDER-001 Phase 1/2 clinical trial of SQZ-eAPC-HPV in patients who have HPV16+ solid tumors, including head and neck, cervical, and anal cancers, and have progressed following standard therapies.
Bobby Carlton in News
HTC is bringing physical therapy, occupational therapy, and pain management treatments to the metaverse.
HTC VIVE is partnering with XRHealth to bring healthcare into the metaverse in the form of virtual medical rooms where patients can receive physical therapy, occupational therapy, and pain management treatments. These digital facilities will be accessible in VR using either a VIVE Focus 3 or VIVE Flow headset, depending on if you are the doctor or the patient.
Verseau Therapeutics Announces FDA Clearance of Investigational New Drug Application for VTX-0811, a PSGL-1 Targeting Monoclonal Antibody
BEDFORD Mass. – January 4, 2022 – Verseau Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application for its lead investigational product candidate, VTX-0811, a monoclonal antibody that binds to P-selectin glycoprotein ligand-1 (PSGL-1). VTX-0811 repolarizes macrophages, leading to coordinated anti-tumor immune responses. The FDA has completed its 30-day safety review and granted approval for the company to proceed with the proposed first-in-human clinical trial of VTX-0811.